Raloxifene Use for The Heart
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
Cardiovascular Diseases|Breast Neoplasms
DRUG: raloxifene|DRUG: placebo
Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.|Time to first occurrence of invasive breast cancer after an expected 5 to 7.5 years of follow-up.
After an expected 5 to 7.5 years of follow-up:|Cardiovascular death, non-fatal MI, hospitalized acute coronary syndrome other than MI, myocardial revascularization, and stroke (individually and combined)|All-cause hospitalization and mortality|Non-coronary artery revascularization|Non-traumatic lower extremity amputation|Fractures|Venous thromboembolism.
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.